위궤양 치료제 시장 : 세계 예측(2026-2032년)

The Peptic Ulcer Medication Market is projected to grow by USD 4.06 billion at a CAGR of 8.29% by 2032.

Peptic Ulcer Medication: Executive Summary

Peptic ulcer medication encompasses therapies used to heal gastric and duodenal ulcers, relieve symptoms, and reduce recurrence risk. Treatment decisions increasingly reflect the underlying cause-especially Helicobacter pylori infection, nonsteroidal anti-inflammatory drug exposure, acid hypersecretion, and complications such as bleeding or perforation. The market is shaped by evidence-based diagnosis, antimicrobial stewardship, medication adherence, safety monitoring, and access to essential medicines.

Treatment Is Shifting Toward Cause-Specific, Safer Care

Clinical practice is moving from symptom suppression alone toward cause-specific management that combines acid suppression, eradication of H. pylori when confirmed, review of ulcerogenic medicines, and follow-up for healing or recurrence. More cautious prescribing is also emerging around prolonged acid suppression, drug interactions, antimicrobial resistance, and vulnerable populations. Diagnostic testing, guideline-based treatment pathways, and coordinated care between primary care, gastroenterology, pharmacy, and hospital services are becoming increasingly important.

Artificial Intelligence Supports Diagnosis, Adherence, and Safety

Artificial intelligence can contribute to peptic ulcer care by helping interpret endoscopic images, prioritize abnormal findings, identify patients at risk of gastrointestinal bleeding, and support medication-reconciliation workflows. Predictive tools may also help clinicians identify likely treatment failure or nonadherence, while conversational systems can reinforce dosing instructions and follow-up reminders. These applications require representative validation, transparent performance measures, privacy safeguards, and clinician oversight because false negatives, biased training data, and inappropriate antibiotic recommendations could create material clinical harm.

Regional Insights: Access and Clinical Capacity Define Outcomes

North America generally benefits from advanced diagnostic and endoscopic capacity but continues to manage concerns related to polypharmacy, antimicrobial resistance, opioid and anti-inflammatory medicine exposure, and unequal access. Latin America faces variation in diagnostic availability, medicine affordability, and H. pylori resistance patterns, making locally informed protocols important. Europe combines strong guideline infrastructure with aging populations, antimicrobial-stewardship priorities, and differences in reimbursement across countries. The Middle East is characterized by uneven specialist capacity, substantial variation in healthcare access, and the need for reliable diagnostic pathways. Africa requires stronger supply continuity, affordable testing, and expanded capacity for recognizing and managing ulcer complications. Asia-Pacific contains highly diverse healthcare systems, with major opportunities to improve early diagnosis, eradication testing, rural access, and resistance surveillance.

Group Insights: Economic and Policy Blocs Shape Treatment Pathways

ASEAN markets require approaches that account for varied insurance coverage, urban-rural access, medicine procurement systems, and differing resistance profiles. BRICS countries span substantial differences in public-sector capacity, affordability, diagnostic infrastructure, and local treatment guidance, making adaptable implementation models valuable. The European Union benefits from cross-border regulatory and clinical collaboration while retaining national differences in reimbursement and care delivery. G7 systems typically have comparatively mature diagnostic and pharmacovigilance capabilities, but must address aging populations, complex medication use, and equitable access. GCC countries have opportunities to expand specialist services and standardized pathways while managing dependence on imported medicines and varied workforce capacity. NATO members represent diverse health systems, where preparedness, continuity of essential medicines, and interoperable clinical guidance are relevant alongside routine ulcer care.

Country Insights: Diverse Priorities Across Major Health Systems

Australia emphasizes evidence-based prescribing, antimicrobial stewardship, and access across geographically dispersed communities. Brazil must balance public-system reach with regional disparities in diagnostics, affordability, and specialist capacity. Canada faces distance-related access barriers and the needs of older adults with complex medicine regimens. China combines expanding diagnostic capability with large population diversity and continuing attention to H. pylori management and resistance. France, Germany, Italy, and Spain operate within well-developed European care environments while addressing aging, reimbursement variation, and appropriate long-term acid-suppression use. India has major opportunities to improve affordable testing, treatment adherence, and rural and public-sector access. Japan and South Korea have strong healthcare infrastructure but must manage aging-related polypharmacy, prevention of recurrence, and evolving resistance concerns. Mexico faces uneven access to testing and specialist care across regions. Russia requires attention to supply continuity, diagnostic quality, and geographic disparities. The United Kingdom prioritizes guideline adherence, antimicrobial stewardship, and timely referral for alarm symptoms. The United States combines extensive treatment availability with challenges involving care fragmentation, medication overuse, health inequities, and rising resistance concerns.

Action Priorities for Leaders: Improve Diagnosis, Safety, and Continuity

Industry leaders should strengthen cause-specific pathways that connect testing, treatment selection, adherence support, and confirmation of eradication where clinically indicated. They should invest in resistance surveillance and responsible antimicrobial use, while supporting formulations and packaging that reduce administration errors. Partnerships with health systems can expand pharmacist-led medication reviews, discharge education, and follow-up for patients at risk of recurrence or bleeding. Digital and AI-enabled tools should be introduced through prospective validation, human oversight, cybersecurity controls, and clear accountability. Access strategies should address affordability, rural delivery, essential-medicine availability, and culturally appropriate education rather than relying solely on product availability.

Research Methodology: Evidence-Led Market Synthesis

This executive summary uses the supplied market definition-peptic ulcer medication-and organizes the assessment around established clinical drivers, treatment pathways, healthcare-system conditions, and geographic variation. Insights should be validated through peer-reviewed clinical literature, treatment guidelines, regulatory communications, pharmacovigilance records, antimicrobial-resistance surveillance, healthcare utilization evidence, and structured interviews with qualified clinicians and pharmacists. Regional, group, and country comparisons should distinguish documented evidence from interpretation and should be updated as diagnostic standards, resistance patterns, safety findings, and access conditions change.

Conclusion: Durable Value Depends on Better Ulcer Care

The peptic ulcer medication landscape is increasingly defined by precision in diagnosis, responsible acid suppression, effective H. pylori management, and prevention of avoidable complications. Differences in resistance, healthcare access, specialist capacity, and medicine continuity mean that successful strategies must be locally adaptable. Leaders that combine clinical evidence, stewardship, adherence support, equitable delivery, and carefully governed digital innovation will be best positioned to improve outcomes while strengthening the sustainability and safety of ulcer care.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. New Revenue Opportunities
• 3.4. Next-Generation Business Models
• 3.5. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Peptic Ulcer Medication Market, by Drug Type

• 7.1. Introduction
• 7.2. H2 Receptor Antagonists
  • 7.2.1. Cimetidine
  • 7.2.2. Famotidine
  • 7.2.3. Nizatidine
  • 7.2.4. Ranitidine
• 7.3. Mucosal Protectants
  • 7.3.1. Bismuth Subsalicylate
  • 7.3.2. Sucralfate
• 7.4. Proton Pump Inhibitors
  • 7.4.1. Esomeprazole
  • 7.4.2. Lansoprazole
  • 7.4.3. Omeprazole
  • 7.4.4. Pantoprazole
  • 7.4.5. Rabeprazole
• 7.5. Synthetic Prostaglandins

8. Peptic Ulcer Medication Market, by Dosage Form

• 8.1. Introduction
• 8.2. Capsules
• 8.3. Injectable
• 8.4. Oral Suspension
• 8.5. Tablets

9. Peptic Ulcer Medication Market, by End User

• 9.1. Introduction
• 9.2. Adult
• 9.3. Geriatric
• 9.4. Pediatric

10. Peptic Ulcer Medication Market, by Distribution Channel

• 10.1. Introduction
• 10.2. Hospital Pharmacies
• 10.3. Online Pharmacies
• 10.4. Retail Pharmacies

11. Peptic Ulcer Medication Market, by Region

• 11.1. Introduction
• 11.2. Asia-Pacific
• 11.3. North America
• 11.4. Latin America
• 11.5. Europe
• 11.6. Middle East
• 11.7. Africa

12. Peptic Ulcer Medication Market, by Group

• 12.1. Introduction
• 12.2. ASEAN
• 12.3. GCC
• 12.4. European Union
• 12.5. BRICS
• 12.6. G7
• 12.7. NATO

13. Peptic Ulcer Medication Market, by Country

• 13.1. Introduction
• 13.2. United States
• 13.3. Canada
• 13.4. Mexico
• 13.5. Brazil
• 13.6. United Kingdom
• 13.7. Germany
• 13.8. France
• 13.9. Russia
• 13.10. Italy
• 13.11. Spain
• 13.12. China
• 13.13. India
• 13.14. Japan
• 13.15. Australia
• 13.16. South Korea

14. Competitive Landscape

• 14.1. Market Share Analysis, 2025
• 14.2. Market Concentration Analysis, 2025
  • 14.2.1. Concentration Ratio (CR)
  • 14.2.2. Herfindahl Hirschman Index (HHI)
• 14.3. Recent Developments & Impact Analysis, 2025
• 14.4. Product Portfolio Analysis, 2025
• 14.5. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. Abbott Laboratories
• 15.2. AstraZeneca PLC
• 15.3. Aurobindo Pharma Limited
• 15.4. Bayer AG
• 15.5. Cipla Limited
• 15.6. Dr. Reddy's Laboratories Ltd
• 15.7. Eli Lilly and Company
• 15.8. GlaxoSmithKline plc
• 15.9. Lupin Limited
• 15.10. Merck & Co Inc
• 15.11. Novartis AG
• 15.12. Pfizer Inc
• 15.13. Roche Holding AG
• 15.14. Sanofi S.A.
• 15.15. Sun Pharmaceutical Industries Ltd
• 15.16. Takeda Pharmaceutical Company Limited
• 15.17. Zydus Lifesciences Ltd

16. Key Experts